Flamingo Therapeutics Announces Poster Presentation on the Immune-Modulatory Effects of Danvatirsen at the American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
abstract has been accepted for presentation at the American Association for Cancer Research (AACR) annual meeting being held in Chicago, IL from April 25-30, 2025 Poster presentation details are as follows: Poster Title: "ASO-mediated STAT3 knockdown relieves immunosuppression sensitizing tumors to immunotherapies" Session Category/Title: Immunology/Modulation of Tumor Microenvironment: Enhancing Immunogenicity and Counteracting Suppression Session Time: 9:00:00 AM 12:00:00 PM Location: Poster Section 38 Published Abstract Number: 2244 For more information, please visit the AACR Annual Meeting 2025 website About Flamingo Therapeutics Flamingo is pioneering RNA-targeted therapies for oncology with a clinical-stage pipeline targeting undruggable transcription factors and long non-coding RNAs. Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Abrdn (formerly funds managed by Tekla Capital Management LLC),
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Pharmaceuticals (NASDAQ:IONS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- Ionis Pharmaceuticals (NASDAQ:IONS) was given a new $100.00 price target on by analysts at Leerink Partners.MarketBeat
- GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Bank of America Corporation from $86.00 to $97.00. They now have a "buy" rating on the stock.MarketBeat
- Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
IONS
Earnings
- 10/29/25 - Beat
IONS
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144/A
- 12/1/25 - Form 144
- IONS's page on the SEC website